Summary: In December's podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the conditional authorisation process for medicines and the need for clearer labelling of medicines that have been through this approval processes. The editors also consider common sources of information on medicines for patients and review a case of interstitial lung disease associated with adalimumab. <p>Read the issue: https://dtb.bmj.com/content/56/12.</p>
